Paper Details

  1. Home
  2. Paper Details

An unusual case of checkpoint-inhibitor-induced pleuropericarditis.

Author: FerrisAllison, FinkeAna C, FosterJennifer, HospedalesEmilio, PerezErnesto, SharifzadehArya, SuarezZoilo K

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study discusses the adverse events associated with pembrolizumab, an immune checkpoint inhibitor. Cardiotoxicity is a rare but potential adverse event, occurring in 1% of cases.
Paper Details　
Original Abstract of the Article :
Pembrolizumab is an immune checkpoint inhibitor that promotes effector T-cell functions on malignant cells by binding to programmed cell death protein 1 (PD-1). Pembrolizumab is well tolerated in most cases with an adverse event profile consisting mainly of pruritus, fatigue, and anorexia. Cardiotox...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/10781552231179369

データ提供：米国国立医学図書館（NLM）

An Unusual Case of Checkpoint-Inhibitor-Induced Pleuropericarditis

Pembrolizumab, a type of immunotherapy known as a checkpoint inhibitor, is a powerful tool in fighting cancer. It works by boosting the immune system's ability to target and destroy cancer cells. While generally well-tolerated, pembrolizumab can sometimes cause side effects, including cardiotoxicity. This study presents an unusual case of a patient who developed pleuropericarditis, an inflammation of the lining of the lungs and heart, after receiving pembrolizumab. This highlights the importance of monitoring for potential side effects and understanding the complex interplay between immunotherapy and the body's immune system.

A Case of Uncommon Side Effects

The authors report a rare instance of pembrolizumab-induced pleuropericarditis, emphasizing the importance of recognizing and managing potential adverse effects. This case serves as a reminder that even seemingly safe medications can have unforeseen consequences. It highlights the need for ongoing vigilance and careful monitoring of patients receiving checkpoint inhibitors.

Navigating Immunotherapy

This case report underscores the complexities of immunotherapy and the importance of a multidisciplinary approach to patient care. Healthcare professionals need to stay abreast of potential side effects and work collaboratively to address these challenges, ensuring optimal patient safety and well-being. It's essential to consult with a healthcare professional for any concerns regarding immunotherapy and to discuss potential risks and benefits.

Dr. Camel's Conclusion

This study reminds us that even in the world of cutting-edge medicine, unforeseen challenges can arise. While immunotherapy offers tremendous hope for cancer patients, careful monitoring and a vigilant approach are essential to manage potential side effects. This case highlights the importance of ongoing research and collaboration to better understand the intricacies of immunotherapy and ensure the safety and well-being of patients.

Date :
  1. Date Completed 2023-10-25
  2. Date Revised 2023-10-25
Further Info :

Pubmed ID

37254508

DOI: Digital Object Identifier

10.1177/10781552231179369

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.